1 year ago
Haematologica: The Best Response Rate of CD19 CAR-T Cell Treatment for Lymphoma was 77% CD19 CAR-T Cell Therapy in Different Subtypes of Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL) CD19 CA...
1 year ago
Brief Introduction of CAR-T Cell Therapy Kymriah (Tisagenlecleucel) Kymriah is a CD19-directed genetically modified autologous T-cell immunocellular therapy, in which the CD19 chimeric antigen rece...
1 year ago
**Chinese Innovation in Medicine: A New Milestone in Small Cell Lung Cancer Treatment!** Small Cell Lung Cancer In the field of medicine, each new drug represents a leap forward in disease treatm...
1 year ago
Brief Introduction of CAR-T Cell Therapy Breyanzi (Lisocabtagene Maraleucel) Breyanzi Brief Introduction Breyanzi (Lisocabtagene Maraleucel) is a CAR-T therapy developed by the global biopharmaceut...
1 year ago
Brief Introduction of CAR-T Cell Therapy Brexucabtagene Autoleucel(Tecartus) Brexucabtagene Autoleucel Receives First Marketing Approval On July 24, 2020, the U.S. Food and Drug Administration (FDA...
1 year ago
Brief Introduction of CAR-T Cell Therapy Axicabtagene Ciloleucel(Yescarta) 1. Composition Axicabtagene Ciloleucel (Yescarta) is a personalized immunocellular therapy that modifies a patient’s...
1 year ago
**Historic Moment! Chinese Medical Team Successfully Cures Diabetes Patient** Diabetes In an exhilarating milestone moment, China’s medical technology has reached new heights! In a ground...
1 year ago
Exploring CAR-T Therapy: Advantages and Challenges CAR-T Therapy CAR-T therapy, as an emerging immunotherapy approach, is gradually attracting attention. Its advantages in the field of canc...
1 year ago
Exploring China’s Indigenous Drug Anlotinib: A Beacon of Hope for Digestive Tract Tumor Patients China’s Indigenous Drug In the continuous advancement of medicine, Anlotinib comb...
1 year ago
Multiple Myeloma Therapy China, Bispecific BCMA/CD19 CAR-T Cell Therapy Opens New Era in the Treatment of Relapsed/Refractory Multiple Myeloma Cao Jiang, Xu Kailin, professors from the Department o...
1 year ago
2024 EBMT|Latest Data Disclosure on China’s Harvesting of RRMM CAR-T Cell Therapy Equecabtagene Autoleucel (CT103a): Efficacy Unaffected by Patients’ Baseline sBCMA Plasma Levels In rec...
1 year ago
China’s Second CAR-T Cell Therapy Zevorcabtagene Autoleucel (CT053) Approved for Treatment of Multiple Myeloma 2024 seems to be a bumper year for cell therapy. Following the global launch of ...
By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.
© Copyright 2023 Advanced Medicine In China. All rights reserved.
